EyePoint Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>EP</div>
EYPT -- USA Stock  

USD 10.23  0.73  6.66%

The upcoming quarterly report is expected on the 4th of March 2021. The stock just had it stock split. EyePoint Pharmaceuticals has reported 1 for 10 split on 9th of December 2020. EyePoint Pharmaceuticals Price to Book Value is comparatively stable at the moment as compared to the past year. EyePoint Pharmaceuticals reported Price to Book Value of 23.14 in 2020. Price to Sales Ratio is likely to gain to 9.37 in 2021, whereas Free Cash Flow is likely to drop (52.6 M) in 2021. While some baby boomers are getting worried about healthcare space, it is reasonable to review EyePoint Pharmaceuticals as an investment alternative. What exactly are EyePoint Pharmaceuticals shareholders getting in February?
Published over two weeks ago
View all stories for EyePoint Pharmaceuticals | View All Stories
You think EyePoint Pharmaceuticals (NASDAQ:EYPT) debt is an issue for private investors?
The company currently holds 53.87 M in liabilities with Debt to Equity (D/E) ratio of 7.09, indicating EyePoint Pharmaceuticals may have difficulties to generate enough cash to satisfy its financial obligations. On a scale of 0 to 100, EyePoint Pharmaceuticals holds a performance score of 10. The firm shows a Beta (market volatility) of 1.7082, which means a somewhat significant risk relative to the market. Let's try to break down what EyePoint's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, EyePoint Pharmaceuticals will likely underperform. Although it is vital to follow EyePoint Pharmaceuticals historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. The philosophy towards predicting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-eight technical indicators for EyePoint Pharmaceuticals, which you can use to evaluate the performance of the firm. Please utilizes EyePoint Pharmaceuticals total risk alpha, as well as the relationship between the downside variance and daily balance of power to make a quick decision on whether EyePoint Pharmaceuticals price patterns will revert.
EyePoint Pharmaceuticals financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures the total debt position of EyePoint Pharmaceuticals, including all of EyePoint Pharmaceuticals's outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of EyePoint Pharmaceuticals assets, the company is considered highly leveraged. Understanding the composition and structure of overall EyePoint Pharmaceuticals debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business is and if it is worth investing in it. Please read more on our technical analysis page.

Understanding EyePoint Total Liabilities

EyePoint Pharmaceuticals liabilities are broken down into two parts on the balance sheet. These are short-term (or current) obligations and long-term debt. EyePoint Pharmaceuticals has to fulfill its short-term liabilities in this reporting year and should be no more than 12 months old. Long-term debt, on the other hand, is anything beyond the 12-month payment timeframe. Common short-term liabilities found on EyePoint Pharmaceuticals balance sheet include debt obligations and money owed to different EyePoint Pharmaceuticals vendors, workers, and loan providers. Below is the chart of EyePoint short long-term liabilities accounts currently reported on its balance sheet.
You can use EyePoint Pharmaceuticals financial leverage analysis tool to get a better grip on understanding its financial position

How important is EyePoint Pharmaceuticals's Liquidity

EyePoint Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance EyePoint Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. EyePoint Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between EyePoint Pharmaceuticals's total debt and its cash.

A Deeper look at EyePoint

EyePoint Pharmaceuticals reported the previous year's revenue of 35.94 M. Net Loss for the year was (40.34 M) with profit before overhead, payroll, taxes, and interest of 2.31 M.

Asset Breakdown

38.8 M
Assets Non Current
34.3 M
39.8 M
Current Assets
Total Assets90.54 Million
Current Assets39.8 Million
Assets Non Current38.78 Million
Goodwill34.33 Million

Our perspective of the newest EyePoint Pharmaceuticals gain

The semi variance is down to 17.28 as of today. EyePoint Pharmaceuticals exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate EyePoint Pharmaceuticals individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about EyePoint Pharmaceuticals future systematic risk.

Our Final Take On EyePoint Pharmaceuticals

Whereas some firms within the biotechnology industry are still a little expensive, even after the recent corrections, EyePoint Pharmaceuticals may offer a potential longer-term growth to private investors. In closing, as of the 4th of January 2021, our latest 30 days 'Buy-vs-Sell' recommendation on the firm is Strong Sell. We believe EyePoint Pharmaceuticals is overvalued with high probability of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of EyePoint Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com